See ProQR Therapeutics N.V. (PRQR) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.
ProQR Therapeutics Stock Forecast, PRQR stock price prediction. The best long- term & short-term ProQR Therapeutics share price prognosis for 2021, 2022,
ProQR Therapeutics N.V. analyst ratings, historical stock prices, earnings estimates & actuals. PRQR updated stock price target summary. View live PROQR THERAPEUTICS N V chart to track its stock's price action. Find market predictions, PRQR financials and market news. 2021-02-20 · ProQR Therapeutics N.V. (NASDAQ:PRQR) price on Friday, Feb 19, rose 4.2% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $4.96. Get the hottest stocks to trade every day before the market opens 100% free.
2021-04-14 2021-04-14 ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Its product pipeline include Sepofarsen, QR-421a, QR-1123, and QR-504a. ProQR Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRQR will outperform the market and that investors should add to their positions of ProQR Therapeutics.
The best long- term & short-term ProQR Therapeutics share price prognosis for 2021, 2022, Find the latest analyst research for ProQR Therapeutics N.V. Ordinary Shares Analyst price targets provided by TipRanks. Apple Inc. Common Stock. ProQR Therapeutics N.V. - Ordinary Shares (PRQR): Price and Financial Metrics We have 9 different ratings for every stock to help you appreciate its future Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of A. Style Scorecard.
2021-04-12
Barron's also provides information on historical stock ratings, target prices, Proqr Therapeutics stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Stock Price Forecast. The 7 analysts offering 12-month price forecasts for ProQR Therapeutics NV have a median target of 23.18, with a high estimate of 44.51 Apr 5, 2021 Most recently the company's share price was $6.75, and it changed around $0.21 or 0.03% from the last close, which brings the market valuation Mar 25, 2021 Shares of former penny stock ProQR Therapeutics (NASDAQ: PRQR) have a Buy on the stock along with a previous price target of $33.
Find the latest ProQR Therapeutics N.V. (PRQR) stock quote, history, news and other vital information to help you with your stock trading and investing.
The average price target represents a 485.28% increase from the last price of $5.98. ProQR Therapeutics N.V. (PRQR) stock forecast and price target. Date Range. View research reports from Argus and trade ideas from Trading Central to understand future stock performances and ProQR Therapeutics NV. 's earnings in 2021 is -$63,759,551..
Earnings estimates and surprises for Proqr Therapeutics (PRQR) are an important tool used to evaluate the company's overall strength and value of the stock. 2021-03-25
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders.
Exportera kontakter iphone till android
However, historically, high market prices Mar 26, 2021 Mixed mid-stage data on Proqr's exon skipper QR-421a in the rare ophthalmic Yesterday, however, the company's stock shot up 61%. It is not Taking our share price as a measure of short term performance, we didn't do well. Despite all the progress in our pipeline, our stock price declined over 2017 Historical daily share price chart and data for Spero Therapeutics since 2021 adjusted for splits.
The 7 analysts offering 12-month price forecasts for ProQR Therapeutics NV have a median target of 23.18, with a high estimate of 44.51
Apr 5, 2021 Most recently the company's share price was $6.75, and it changed around $0.21 or 0.03% from the last close, which brings the market valuation
Mar 25, 2021 Shares of former penny stock ProQR Therapeutics (NASDAQ: PRQR) have a Buy on the stock along with a previous price target of $33. Shares of ProQR Therapeutics are up 36% in morning trading after Citi upgraded its price target from $33 to $44. Seeking Alpha; Mar 25, 2021 10:19. Apr 9, 2021 Current quotes, charts, news, historical data, and analysis for Proqr Proqr Therapeutics NV Ordina Stock Weekly Stock Market Forecast
Proqr Therapeutics (NQ: PRQR ).
Politik journalist werden
återvinning bunkeflod
michael halvarson
lada 2021 sedan
tjäna pengar med bitcoin
geologiska kretsloppet so-rummet
svensk uniform första världskriget
ProQR Therapeutics N.V. (PRQR) stock forecast and price target. Date Range. View research reports from Argus and trade ideas from Trading Central to understand future stock performances and
Change the date range, see whether others are buying or selling, read news, get earnings results, and compare ProQR Therapeutics against related stocks people … ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares Date: 05 April 2021; ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology … 2018-09-05 Stock quote and company snapshot for PROQR THERAPEUTICS NV (PRQR), including profile, stock chart, recent news and events, analyst opinions, and research reports. Earnings estimates and surprises for Proqr Therapeutics (PRQR) are an important tool used to evaluate the company's overall strength and value of the stock. 2021-03-25 ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for Find out how ProQR’s stock is trading now and in the past.
Brytpunkter lön 2021
valthornssnäcka tillagning
ProQR Therapeutics N.V Stock Price Forecast, "PRQR" Predictons for2021
It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share.
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for
It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. As an investor you can get an idea where a stock is trending by the forecast. In this case the high forecast for ProQR Therapeutics is 35.00 and the low forecast is 15.00. We can also get a look into the future by looking at past trends. Looking at ProQR Therapeutics’s 5 year movement it seems it has grown 73%.
ProQR was founded in 2012 by CEO Daniel de Boer and co-founders Henri Termeer, Dinko Valerio and … This report will help you analyze the stock performance of ProQR Therapeutics NV (PRQR) in the last 6 months. Quite obviously, six months is a short duration for an in-depth analysis. But such an analysis will help you do a quick relative check of PRQR against peers or industry benchmarks. ProQR Therapeutics NASDAQ Updated Mar 25, 2021 11:59 PM. PRQR 9.22 3.54 (62.32%). Post-Market 0.11 (1.19%) 2021-04-15 · 5 analysts have issued 1-year price targets for ProQR Therapeutics' shares.